Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to identify new chemotherapy treatment regimens with better response rates and to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Georgia Center for Oncology Research & Education
• Collaborator: Sanofi
• Treatments: Capecitabine; Docetaxel

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed breast carcinoma.

• Early stage breast cancer (stage 1, 2, 3).

• No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.

• 18 years of age or older.

• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Exclusion Criteria:

• Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.

• Major surgery within 28 days of study entry.

• Evidence of CNS metastases.

• Final eligibility for a clinical trial is determined by the health professionals conducting the trial.